When it comes to precision oncology, proteogenomics may provide better prospects to the
clinical characterization of tumors, help make a more accurate diagnosis of cancer, and …

The acquisition of cancer hallmarks requires molecular alterations at multiple levels
including genome, epigenome, transcriptome, proteome, and metabolome. In the past …

The ubiquitin E3 ligase substrate adapter cereblon (CRBN) is a target of thalidomide and
lenalidomide, therapeutic agents used in the treatment of haematopoietic malignancies …

Abstract The Human Proteome Organization (HUPO) launched the Human Proteome Project
(HPP) in 2010, creating an international framework for global collaboration, data sharing …

APOBEC3 enzymes are cytosine deaminases implicated in cancer. Precisely when
APOBEC3 expression is induced during cancer development remains to be defined. Here …

Human papillomaviruses (HPV) are a group of small non-enveloped DNA viruses whose
infection causes benign tumors or cancers. HPV16 and HPV18, the two most common high …

Cancer genomes have been explored from the early 2000s through massive exome
sequencing efforts, leading to the publication of The Cancer Genome Atlas in 2013 …

The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the second
largest source of mutation in cancer. This mutational process may be a causal driver or …

Current algorithms for the clinical management of patients with squamous cell carcinoma of
the head and neck (HNSCC) are based on a stage-dependent strategy where all patients at …

APOBEC cytidine deaminases are the second-most prominent source of mutagenesis in
sequenced tumors. Previous studies have proposed that APOBEC3B (A3B) is the major …